Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2′,2′-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry

Rapid Communications in Mass Spectrometry

Volumn 21, Issue 14, 2007, Pages 2312-2322

  Vainchtein, Liia D ^a,c   Rosing, Hilde ^a   Thijssen, Bas ^a   Schellens, Jan H M ^a,b   Beijnen, Jos H ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRODUCTS; ELECTROSPRAY IONIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHASE SEPARATION; PLASMA (HUMAN); POSITIVE IONS;

AMMONIUM ACETATE; ANTI-CANCER AGENTS; GEMCITABINE; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; HPLC-MS-MS; HUMAN PLASMAS; LIQUID CHROMATOGRAPHY WITH TANDEM MASS SPECTROMETRY (LCMS/MS); QUANTITATIVE DETERMINATIONS; SIMULTANEOUS DETERMINATIONS;

METABOLITES;

EID: 34547188623     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.3096     Document Type: Article

References (27)

1. Barton-Bruke M. Cancer Nurs. 1999; 22: 176.
2. Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM, Peters GJ. Cancer Res. 1994; 54: 4138.
3. Kosmas C, Tsavaris N, Mylonakis N, Kalofonos HP. Crit. Rev. Oncol. Hematol. 2003; 45: 265.
4. Heinemann V. Oncology 2003; 64: 191.
5. Freeman KB, Anliker S, Hamilton M, Osborne D, Dhahir PH, Nelson R, Allerheiligen SRB. J. Chromatogr. B 1995; 665: 171.
6. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W. J. Clin. Oncol. 1991; 9: 491.
7. Krishnan P, Fu Q, Lam W, Liou JY, Dutschman G, Cheng YC. J. Biol. Chem. 2002; 277: 5453.
8. Bouffard DY, Laliberte J, Momparler RL. Biochem. Pharmacol. 1993; 45: 1857.
9. Liou JY, Dutschmen GE, Lam W, Jiang Z, Cheng YC. Cancer Res. 2002; 62: 1624.
10. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W. Mol. Pharmacol. 1990; 38: 567.
11. Ross DD, Cuddy DP. Biochem. Pharmacol. 1994; 48: 1619.
12. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Cancer Res. 1991; 51: 110.
13. Yilmaz B, Kadioglu Y. Farmaco 2004; 18: 1017.
14. Edzes HT, Peters GJ, Noordhuis P, Vermorken JB. Anal Biochem. 1993; 214: 25.
15. Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WDW, Dalbagni G. Clin. Cancer Res. 1999; 9: 2629.
16. Peters GJ, Tonis B, Clavel M, Guastella J, Quick R, Osborne D, Mc Daniel C, van Maanen J, Steenbergen J, van der Vijgh WJF, Pinedo HM, Vermorken J. Proc Am. Assoc. Cancer Res. 1990; 31: 180.
17. Keith B, Xu Y, Grem JL. J. Chromatogr. B 2003; 785: 65.
18. Kirstein MN, Hassan I, Guire DE, Weller DR, Dagit JW, Fisher JE, Remmel RP. J. Chromatogr. B 2006; 835: 136.
19. Bilal Y, Yucel YK, Aksoy Y. J. Chromatogr. B 2003; 791: 103.
20. Wang L, Goh B, Lee H, Noordhuis P, Peters G. Therap. Drug Monit. 2003; 25: 552.
21. Xu Y, Keith B, Crem L. J Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2004; 802: 263.
22. Sottani C, Zuchetti M, Zaffaroni M, Bettinelli M, Minoia C. Rapid Commun. Mass Spectrom. 2004; 18: 1017.
23. U.S. Food and Drug Administration: Centre for Drug Evaluation and Research: Guidance for Industry: Bioanalytical Method Validation. 2001. Available: www.fda.gov/cder/ quidance/4252fnl.htm
24. Stoller RG, Myers CE, Chabner BA. Biochem. Pharmacol. 1978; 27: 53.
25. Cohen RM, Wolfenden R. J. Biol. Chem. 1971; 246: 7561.
26. Rosing H, Man W, Doyle E, Bult A, Beijnen JH. J. Liq. Chromatogr. Related Technol. 2000; 23: 329.
27. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Anal. Chem. 2003; 75: 3019.